SEINE BIO · PEPTIDE PROFILE
Teduglutide
GLP-2 analogue · short bowel syndrome
Approved productGet to know the name, understand the evidence, and prepare a more informed conversation.
What is Teduglutide?
Gattex is a GLP-2 analog for short bowel syndrome in patients dependent on parenteral support. Its clinical use concerns a serious intestinal condition, not ordinary digestive wellness. Source & further reading.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of Teduglutide.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Overview
Teduglutide is a GLP-2 analog used as the prescription medicine Gattex for short-bowel syndrome in patients dependent on parenteral support. Its place in care concerns intestinal failure and nutritional independence. That specialized setting is very different from broad online claims about gut healing, digestive optimization or routine wellness.
Community Use
No exact teduglutide profile from PeptideDosages or Peptidepedia was verified for this article. A community source gap should not be filled with a GLP-1 protocol or a different gut-related peptide. GLP-2 biology and a clinical short-bowel diagnosis do not make informal gut-health anecdotes a treatment standard.
Doses, Durations & Cycles
Published dosing regimens. Product-label and study regimens for education, not instructions for self-treatment. Product, indication and route matter.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous | 0.05 mg/kg daily; 0.025 mg/kg daily when eGFR is below 60 mL/min/1.73 m² | Daily | Ongoing short-bowel-syndrome treatment Break: No routine cycling interval | FDA prescribing information GATTEX |
Important context: This specialist indication does not establish a general gut-wellness regimen.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
The table reflects the labeled daily, weight-based regimen and disease-specific study context. Gattex’s label includes renal dose adjustment and monitoring requirements. Those are clinical decisions, not a wellness dose range or cycle that can be selected from the table.
Research Findings
A 24-week randomized trial compared teduglutide with placebo in short-bowel syndrome with intestinal failure. It measured changes in parenteral support needs. The study’s patient population and care infrastructure are essential context; ordinary digestive symptoms do not reproduce that diagnosis or trial setting.
U.S. Approval & Access
Gattex is an approved prescription treatment for its defined short-bowel indication. DailyMed lists DEA Schedule: None. Unscheduled status does not establish suitability for an unapproved digestive-wellness use or authorize a research preparation as a finished patient-care medicine.
What It Does in the Body
GLP-2-related activity supports intestinal structure and absorption. The label describes a short circulating half-life, while clinical adaptation is assessed over a much longer period. Reliable individual onset, peak reduction in support needs and duration after discontinuation cannot be inferred from drug clearance or a fixed online cycle.
Benefits & Reported Experiences
The randomized study found more reductions in parenteral support with teduglutide than placebo. That does not mean every patient becomes independent of support. A specialist plan should assess meaningful nutritional and functional changes rather than interpreting an intestinal-growth mechanism as a guarantee of restored digestion.
Side Effects & Risks
The label addresses neoplastic growth, intestinal or stomal obstruction, biliary and pancreatic disease and fluid overload. These are reasons for coordinated surveillance, not merely a list of discomforts. Monitoring cannot be replaced by a general inquiry form, a laboratory purity certificate or reassurance from a digestive-wellness testimonial.
Delivery Options
The prescribed medicine is administered subcutaneously within a specialist care plan. Product preparation and patient training are handled by the treating team and pharmacy. This article does not provide reconstitution, injection instructions or an alternative route, and Seine Bio does not offer self-reconstitution powders.
Product Quality & Storage
Gattex storage depends on its specific packaging and dispensing stage. The current label distinguishes refrigerated stock from pharmacist-dispensed kits and their assigned use-by dating. Follow the exact dispensed label rather than assuming one temperature rule fits every kit. Confirm any uncertainty with the specialty pharmacy.
Combinations & Interactions
Changing other treatments or parenteral support requires the intestinal-failure team’s assessment. A stack with growth-related peptides or informal gut products is not established by Gattex trials. Improved absorption can also affect concurrent medicines, making coordinated review more useful than a community combination schedule.
Talking With Your Provider
If you have diagnosed short-bowel syndrome, discuss treatment with the clinician managing nutrition and parenteral support. If you have other digestive concerns, start with an appropriate diagnostic evaluation. Teduglutide’s specific evidence can inform a question, but it does not replace investigating the cause of symptoms or selecting supported care.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
A clinician may recommend a different option—or no medication—after assessing your individual circumstances.
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Bring your curiosity. Start a conversation.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
Create a free account ↗This educational information is free to read. Create a free account to request review of your care goals. Neither an account nor paid membership guarantees a prescription, access to the named compound or research enrollment.
Educational profile · U.S. context · October 7, 2026. This page does not provide personalized medical advice, dosing, or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →